Ketamine Treatment for PTSD and MDD in TBI

This interventional trial (n=40) aims to investigate the efficacy and safety of subanesthetic ketamine in treating depression and post-traumatic stress disorder (PTSD) among Veterans with mild to moderate traumatic brain injury (TBI).

Participants will be randomly assigned to receive either ketamine or midazolam (active placebo) twice a week for 3 weeks. The study will assess the change in severity of depressive symptoms measured by the Montgomery-Åsberg Depression Rating Scale and the severity of PTSD symptoms measured by the PTSD Checklist for DSM-5.

The study is conducted by the Minneapolis Veterans Affairs Medical Center and is estimated to begin in March 2024 and end in March 2027.

Topic PTSD Depression Traumatic Brain Injury
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Minneapolis Veterans Affairs Medical Center
This company doesn't have a full profile yet, it is linked to a clinical trial.

University Hospital Toulouse
The University Hospital of Toulouse (CHU de Toulouse) is a leading medical institution located in Toulouse, France. It provides comprehensive healthcare services, conducts medical research, and offers educational programs for healthcare professionals

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.